Malaria Initiative
Alliances and collaborations are at the heart of the Novartis Malaria Initiative, one of the healthcare industry's largest access-to-medicine programs.
Since 2001, Novartis has worked with a range of organizations to ensure effective delivery of our antimalarial medicine (an artemisinin-based combination therapy, or ACT), providing more than 400 million treatments without profit to more than 60 malaria-endemic countries.
Fighting Malaria
In 2009, ahead of the call from the World Health Organization (WHO) and UNICEF for “child-sized” medicines, Novartis developed a pediatric antimalarial medicine in collaboration with Medicines for Malaria Venture. The sweet-tasting dispersible formulation provides an improved alternative for children, who are most at risk for malaria.
We are proud of the remarkable public heath milestones these efforts and collaborations have helped to achieve.
Our commitments in action
Fighting malaria in Ethiopia
Novartis Italy works with external partners, including the Italian Ministry of Health, to help fight malaria in Tigray, a region in northern Ethiopia. In the first year of the program, 80 000 patients were diagnosed and treated.
The initiative supports a wider effort by Novartis to improve access to medicine and combat malaria worldwide.
